A Mendelian randomization study of the effects of blood lipids on breast cancer risk
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Observational studies have reported inconsistent associations between circulating lipids and breast cancer risk. Using results from >400,000 participants in two-sample Mendelian randomization, we show that genetically raised LDL-cholesterol is associated with higher risk of breast cancer (odds ratio, OR, per standard deviation, 1.09, 95% confidence interval, 1.02–1.18, P = 0.020) and estrogen receptor (ER)-positive breast cancer (OR 1.14 [1.05–1.24] P = 0.004). Genetically raised HDL-cholesterol is associated with higher risk of ER-positive breast cancer (OR 1.13 [1.01–1.26] P = 0.037). HDL-cholesterol-raising variants in the gene encoding the target of CETP inhibitors are associated with higher risk of breast cancer (OR 1.07 [1.03–1.11] P = 0.001) and ER-positive breast cancer (OR 1.08 [1.03–1.13] P = 0.001). LDL-cholesterol-lowering variants mimicking PCSK9 inhibitors are associated (P = 0.014) with lower breast cancer risk. We find no effects related to the statin and ezetimibe target genes. The possible risk-promoting effects of raised LDL-cholesterol and CETP-mediated raised HDL-cholesterol have implications for breast cancer prevention and clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Bowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922
Verbanck, M., Chen, C.-Y., Neale, B., & Do, R. (2018) · Nature Genetics · doi:10.1038/s41588-018-0099-7 · Cited by 8,591
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Machiela, M. J., & Chanock, S. J. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv402 · Cited by 2,069
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomization
Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N., & Thompson, J. (2017) · Statistics in Medicine · doi:10.1002/sim.7221 · Cited by 1,887
EPIC- InterAct Consortium, Burgess, S., Scott, R. A., Timpson, N. J., Davey Smith, G., & Thompson, S. G. (2015) · European Journal of Epidemiology · doi:10.1007/s10654-015-0011-z · Cited by 1,803
Bias due to participant overlap in two‐sample Mendelian randomization
Burgess, S., Davies, N. M., & Thompson, S. G. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21998 · Cited by 1,624
Cited by
Cardiovascular disease and cancer: shared risk factors and mechanisms
Wilcox, N. S., Amit, U., Reibel, J. B., Berlin, E., Howell, K., & Ky, B. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01017-x · Cited by 310
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Fang, S., Yarmolinsky, J., Gill, D., Bull, C. J., Perks, C. M., the PRACTICAL Consortium, Davey Smith, G., Gaunt, T. R., & Richardson, T. G. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1003988 · Cited by 55
“There are various preclinical studies based on tumour tissue or mouse models that report the direct effects of PCSK9 or PCSK9 inhibitors on multiple types of cancer [57], including hepatocellular carcinoma [58,59], lung carcinoma [60,61], colorectal cancer [62], and breast cancer [63].”
BackgroundPCSK9 in metabolism and diseases
Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49
Metadata
- Authors
- Nowak, C., & Ärnlöv, J.
- Venue
- Nature Communications
- Published
- 2018-09-27
- Volume
- 9
- Issue
- 1
- Pages
- 3957-3957
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2890202245
- Cited by
- 190
- References
- 17
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Mendelian randomization study of the effects of blood lipids on breast cancer risk. https://app.cochat.ai/papers/10.1038/s41467-018-06467-9
- The paper
- Nowak, C., & Ärnlöv, J. (2018). A Mendelian randomization study of the effects of blood lipids on breast cancer risk. Nature Communications. https://doi.org/10.1038/s41467-018-06467-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.